ID | 50726 |
フルテキストURL | |
著者 |
Ueno, Tsuyoshi
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
Tsukuda, Kazunori
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
ORCID
Kaken ID
publons
researchmap
Toyooka, Shinichi
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
ORCID
Kaken ID
publons
researchmap
Ando, Midori
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
Takaoka, Munenori
Kawasaki Med Univ, Dept Gen Surg
Soh, Junichi
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
ORCID
Kaken ID
researchmap
Asano, Hiroaki
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
Kaken ID
Maki, Yuho
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
Muraoka, Takayuki
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
Tanaka, Norimitsu
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
Shien, Kazuhiko
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
ORCID
Kaken ID
publons
researchmap
Furukawa, Masashi
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
Yamatsuji, Tomoki
Kawasaki Med Univ, Dept Gen Surg
Kiura, Katsuyuki
Okayama Univ, Dept Hematol Oncol & Resp Med, Grad Sch Med Dent & Pharmaceut Sci
ORCID
Kaken ID
publons
researchmap
Naomoto, Yoshio
Kawasaki Med Univ, Dept Gen Surg
Miyoshi, Shinichiro
Okayama Univ, Dept Gen Thorac Surg, Grad Sch Med Dent & Pharmaceut Sci
Kaken ID
publons
researchmap
|
抄録 | The anti-tumor activity of a newly developed Hsp90 inhibitor, NVP-AUY922 (AUY922), against non-small cell lung cancer (NSCLC) was examined. Twenty-one NSCLC cell lines were used, the somatic alterations of which were characterized. Cell proliferation was analyzed using a modified MTS assay. Expression of the client proteins was assessed using Western blotting. The cell cycle was analyzed using flow cytometry. The IC50 value of AUY922 for the NSCLC cell lines ranged from 5.2 to 860 nM (median, 20.4 nM). Based on previous data, cells with an IC50 of less than 50 nM were classified as sensitive cells and 19 of the 21 NSCLC cell lines were judged to be sensitive. The IC50 of five malignant pleural mesothelioma (MPM) cell lines revealed that the MPM cells had a significantly higher IC50 value (median, 89.2 nM; range, 22.2-24, 100 nM) than the NSCLC cells (p = 0.015). There was significant depletion of both the total and phosphorylated client proteins - EGFR, MET, HERZ and ART - at low drug concentrations (50-100 nM) in drug-sensitive cell lines. Cell-cycle analysis was performed for two sensitive cell lines, H1975 and H838. Following AUY922 treatment, an increase in the sub-G(0)-G(1) cell population, as well as appearance of cleaved PARP expression, indicated the induction of apoptosis. In conclusion, AUY922 was effective against most NSCLC cell lines, independent of the type of known molecular alteration, and appears to be a promising new drug for the treatment of NSCLC. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
|
キーワード | NSCLC
Hsp90
AUY922
EGFR
EGFR-TKI
Mesothelioma
|
発行日 | 2012-04
|
出版物タイトル |
Lung Cancer
|
巻 | 76巻
|
号 | 1号
|
出版者 | Elsevier Ireland Ltd.
|
開始ページ | 26
|
終了ページ | 31
|
ISSN | 0169-5002
|
NCID | AA10785743
|
資料タイプ |
学術雑誌論文
|
オフィシャル URL | http://dx.doi.org/10.1016/j.lungcan.2011.09.011
|
関連URL | http://ousar.lib.okayama-u.ac.jp/metadata/50671
|
言語 |
英語
|
著作権者 | (C) 2011 Elsevier Ireland Ltd. All rights reserved.
|
論文のバージョン | author
|
査読 |
有り
|
DOI | |
Web of Science KeyUT |